安慰剂
重性抑郁障碍
内科学
评定量表
萧条(经济学)
统计显著性
精神科
随机对照试验
人口
心理学
再摄取抑制剂
医学
抗抑郁药
心情
焦虑
发展心理学
宏观经济学
病理
经济
环境卫生
替代医学
作者
David J. Hellerstein,Jonathan W. Stewart,Ying Chen,Vinushini Arunagiri,Bradley S. Peterson,Patrick J. McGrath
标识
DOI:10.1016/j.jad.2018.11.065
摘要
Pharmacotherapy of non-major persistent depressive disorder (PDD) is little studied. We report a study of the serotonin-norepinephrine reuptake inhibitor (SNRI) desvenlafaxine (DVLX) for PDD.Non-psychotic, non-bipolar outpatients aged 20-65 having PDD without concurrent major depression (MDD) were randomized double-blind to desvenlafaxine or placebo for 12 weeks. All had Hamilton Depression Rating Scale (HDRS-24) score ≥ 12. Open-label DVLX was offered for 12 weeks following the acute trial.Seventy-one subjects having mean baseline HDRS-24 20.27 ± 4.77 were eligible, of whom post-RZ data was available for all 59 randomized. The primary 12 week analysis did not differentiate DVLX-treated subjects' mean HDRS scores from those on placebo (6.53 ± 3.98 vs. 8.24 ± 4.96, F = 3.33, df = 1, p = .07). Several secondary analyses yielded statistically significant results, including Responder, CGI and QIDS.As the primary analysis did not reach statistical significance, this is a negative study which does not support the use of DVLX for non-major PDD. Nevertheless, statistically significant secondary analyses suggest the overall negative result could be due to sample size or sampling, suggesting further studies of this medication might be appropriate in this population.
科研通智能强力驱动
Strongly Powered by AbleSci AI